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ABSTRACT
A 37-year-old male patient, Fitzpatrick skin phototype IV, a student living in Belem, 
Amazon region, in 2015 had a confirmed diagnosis of acquired immunodeficiency virus 
(HIV) infection, but did not initiate antiretroviral treatment at his own option. Three years 
after the diagnosis, erythematous maculae appeared on the dorsum of the nose with rapid 
progression to the entire face, with posterior diffuse infiltration and appearance of nodules 
on the chin and shoulder. In December 2018, the patient presented with exacerbation of the 
condition with an increase in infiltrated violaceous plaques and disseminated violaceous 
nodules. A histopathological biopsy of the skin was performed, confirming the diagnosis 
of angiomatoid proliferation suggestive of Kaposi’s sarcoma (KS), with an important 
dissemination of this disease to the noble organs. In addition, it is important to note that he 
only started antiretroviral therapy (ART) after the exacerbation of Kaposi (December 2018). 
In such cases, chemotherapy associated with ART is crucial for the treatment and follow-up 
of the patient, since Kaposi’s sarcoma develops relatively low in patients who do not have 
immunodeficiency.
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INTRODUCTION
HIV infection has become a worldwide public health problem. Over 36 million 
people are estimated to be infected with HIV, and approximately 1.1 million deaths 
were attributed to this infection in 2015. In addition, by the end of 2015, over 
2.1 million new cases were identified. Several skin diseases are almost unique to 
HIV-infected individuals, such as oral hairy leukoplakia, bacillary angiomatosis 
and Kaposi’s sarcoma1.
Kaposi’s sarcoma (KS) is an HIV-related vascular neoplasm associated with 
human herpes virus 8 infections. Cutaneous KS presents as red, violaceous (purple), 
or brown lesions, from macules, patches and papules to nodules or tumors. KS can 
present as skin or mucomembranous lesions, however, disseminated disease may 
affect any organ. The most common sites of disease dissemination include the skin, 
mucosal surfaces, respiratory tract and lymph nodes, and extensive disseminated 
disease is often associated to lymphedema2.
CASE REPORT
In 2015, a 37-year-old male patient, Fitzpatrick skin phototype IV, a student living 
in Belem municipality, Para State, in the Amazon region, had a confirmed diagnosis 
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of acquired immunodeficiency virus (HIV) infection, but he 
chose not to start the antiretroviral treatment at that time. 
Three years after the diagnosis, erythematous maculae 
appeared on the dorsum of the nose with rapid progression 
to the entire face, with posterior diffuse infiltration and 
appearance of nodules on the chin and shoulder (Figure 1a). 
In July 2018, lesions had spread throughout the body 
(Figure 1b, 1c and 1d) and periorbital edema was present. 
At this time, the patient had a CD4 + T lymphocyte 
count of 142 cells/mm3, T CD8 + 1,593 cells/mm3 
and viral load (CV) of 1,556,502 copies/mm³. In view of the 
diagnostic hypothesis of Kaposi’s sarcoma (KS) associated 
to AIDS, the patient accepted to initiate the antiretroviral 
therapy (ART) with the Tenofovir (TDF), Lamivudine 
(3TC) and Dolutegravir (DTG).
In December 2018, the patient presented exacerbation 
of symptomatology and increased infiltrated violaceous 
plaques as well as disseminated violaceous nodules. In view 
of the severity of the case and suspicion of the presence of 
lesions in multiple organs and due to the worsening of the 
clinical symptomatology , an investigation of the possible 
dissemination to inner organs was carried out and the 
patient was admitted to the infectious diseases ward of the 
university hospital, where biopsy of the skin was performed 
for histopathological exams that confirmed the diagnosis of 
angiomatoid proliferation suggestive of Kaposi’s sarcoma 
(KS). The upper digestive endoscopy found a number of 
violaceous plaques (5-7 cm) in the esophagus (Figure 1e), 
and elevated sessile violaceous lesions (5 mm) in the 
stomach and duodenum (Figure 1f) that the diagnosis of 
Figure 1 - Nodules and erythematous-infiltrated plaques with clear borders, irregular, confluent, coalescent and disseminated 
contours on the face (a), auricular pavilion (b), trunk (c) and limbs (d); (e) purple 5-7 cm plaques from the esophagus, proximal to 
the distal point; (f) Elevated sessile, violet, 5 mm lesion in the antral mucosa; (g) elevated, violaceous, hardened lesion covered 
with fibrin in the ileocecal valve; (h) a cyst-like lesion in the left supraglottic region; (i) aspect of lesions after chemotherapy.
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Kaposi’s sarcoma lesions after microscopy. The patient 
underwent a colonoscopy, that evidenced a violaceous 
lesion (3 cm) in the cecal ileum (Figure 1g) and others 
lesions (5 mm-2 cm) in cecum, colon and rectum. These 
lesions appeared to be hardened, ulcerated, and covered 
by a fibrin clot. Histopathologic examination confirmed 
the clinical suspicion of KS. In bronchoscopy, there were 
nodules in the larynx and in the supraglottic region on 
the left side (Figure 1h), in addition to red-violet-colored 
mucosa in the lateral wall and medial segmentation in the 
middle lobe bronchus (MLB), on the right bronchial tree. 
The mucosa had a red-violet color at the entrance of the 
lingual bronchus and at the entrance of the apical segment 
of the upper lobar bronchus (ULB) on the left bronchial tree. 
In addition, it is important to clarify that he only 
accepted to initiate ART, with the drugs Tenofovir (TDF), 
Lamivudine (3TC) and Dolutegravir (DTG), in December, 
after the Kaposi’s exacerbation. The patient started his first 
chemotherapy session with Paclitaxel at the end of December 
2018, and was discharged after 10 days (Figure 1i) with 
sulfamethoxazole-trimethoprim prophylaxis, and has been 
followed-up by oncologists, dermatologists and infectious 
diseases oncologists, dermatologists and infectious diseases 
specialists. 
This year (2019), the patient has been clinically 
improving after the beginning of the treatment. More 
recently, control exams presented CD4+ lymphocyte count 
of 45 cells/mm3, T CD8+ 850 cells/mm3, CD4+/CD8+ 
ratio of 0.05 and viral load of 52 mmc copies. A significant 
reduction in viral load at nine months with satisfactory 
disease evolution compared to baseline is highlighted.
DISCUSSION
The disseminated presentation of AIDS-associated 
KS has an extremely poor prognostic scenario in the vast 
majority of cases, spreading rapidly and progressively 
and often being fatal3. Diagnosis by histopathological 
examination is the gold standard4 and the early diagnosis 
is of essential importance for the elaboration of an efficient 
therapeutic strategy for the control of the disease. The 
disseminated form of the disease may manifest on the skin, 
oral mucosa, gastrointestinal tract, lymph nodes and lungs5 
similar to the patient presented here. This symptomatology, 
CD4 cell count lower than 150 cells per mm3, the presence 
of systemic disease, as well as pulmonary involvement 
exhibiting T1, I1 and S1 staging are high risk factors and 
they have been associated with a poor outcome and patients’ 
death6. 
In these cases, chemotherapy associated with ART is 
very important for the treatment and follow-up of patients, 
as the percentage of KS in patients who do not have 
immunodeficiencies are relatively uncommon5. Paclitaxel 
is an accepted option as the treatment of choice associated 
with “pegylated liposomal doxorubicin”, but it has a higher 
myelotoxic potential, may cause total alopecia and also 
requires care due to the possibility to increase HAART 
reactions6.
The differencial diagnosis of Kaposi’s sarcoma 
mimickers includes deep fungal infections, vascular 
malignant neoplasms and vasculopathic disorders. 
Cutaneous manifestations of pneumocystosis may also 
show violaceous papules and nodules, but will also have 
pulmonar involvement and the Gomori methenamine-silver 
(GMS) staining will show typical cysts of Pneumocystis 
jirovecci7. In addition, Zygmycosis or Mucormycosis, an 
Entomophtoromycosis will also presentviolaceous nodules 
in diabetic patients, in extensive burn or trauma areas and 
GMS is the best method to evidence fungal hyphae in 
tissues due to a high contrast with minimal background 
impregnation. The histopathological examination revealed 
tissue alterations, such as mixed inflammatory infiltrate, 
necrosis, thrombosis and angioinvasion by the fungal 
hyphae8. Angiosarcoma, a malignant vascular tumor, shows 
nuclear pleomorphism and atypical vascular channels, so 
it can easily be distinguished from KS by histopathology. 
Calciphylaxis shows occlusion of vascular vessels in 
subcutaneous fat with calcium deposition. In conclusion, 
when a patient presents with violaceous papules and 
nodules, the clinical investigation (appearance of lesions 
and the patient’s history) will be best complemented by 
histopathological analyses. 
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